Artiva Biotherapeutics (ARTV) CFO Krishnamohan gave up 3,490 shares at $3.25 to cover taxes or an exercise price
Insider transactions reported
Neha Krishnamohan (Chief Financial Officer at Artiva Biotherapeutics Inc., ARTV) reported that they gave up 3,490 shares at $3.25 to cover taxes or an exercise price on Nov 15, 2025. After these transactions the filing shows 99,356 shares held directly.
- Reporting person
- Krishnamohan Neha
- Role
- Chief Financial Officer
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Nov 15, 2025 | Shares withheld for taxes or exercise price (F) | Common Stock1 | -3,490 | $3.25 | $11.3K | 99,356 direct |
Holdings before and after
- Common Stock: 102,846 to 99,356 direct
Footnotes from the filing
- 1. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.
Transaction codes in this filing
- Shares withheld for taxes or exercise price:
- Code F marks shares handed back or withheld to pay taxes or an exercise price. No sale happens in the market.
FAQ
What did Krishnamohan report in this ARTV Form 4?
Neha Krishnamohan (Chief Financial Officer at Artiva Biotherapeutics Inc., ARTV) reported that they gave up 3,490 shares at $3.25 to cover taxes or an exercise price on Nov 15, 2025. After these transactions the filing shows 99,356 shares held directly.
How many ARTV shares does Krishnamohan hold after this filing?
The filing shows 99,356 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code F mean on an SEC Form 4?
Code F marks shares handed back or withheld to pay taxes or an exercise price. No sale happens in the market.
Historical context for ARTV
Across the 3 sessions after earlier ARTV headlines, the stock closed higher 2 times and lower 1 times, with a median move of 5.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ARTV | SPY |
|---|---|---|---|
| Nov 12, 2025 | Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Diseaseand 1 other headline that session | +10.9% | +0.1% |
| Nov 4, 2025 | Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK® | -4.8% | -1.2% |
| Oct 31, 2025 | Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November | +5.8% | +0.3% |
Earlier insider filings at ARTV
- Nov 18, 2025President and CEO Aslan Fred sold $21,522 worth of shares (6,375 units at $3.38) and covered exercise/tax liability with 6,347 shares, decreasing direct ownership by 4% to 343,999 units (SEC Form 4)
- Oct 18, 2025President and CEO Aslan Fred sold $153,000 worth of shares (25,500 units at $6.00), decreasing direct ownership by 7% to 356,721 units (SEC Form 4)
- Aug 19, 2025Chief Financial Officer Krishnamohan Neha covered exercise/tax liability with 7,154 shares, decreasing direct ownership by 7% to 102,846 units (SEC Form 4)
- Aug 19, 2025President and CEO Aslan Fred covered exercise/tax liability with 8,944 shares and sold $69,579 worth of shares (25,500 units at $2.73), decreasing direct ownership by 8% to 382,221 units (SEC Form 4)
- Aug 19, 2025SVP, Research and Development Raymon Heather covered exercise/tax liability with 2,384 shares, decreasing direct ownership by 5% to 40,966 units (SEC Form 4)
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2024
Follow ARTV and get a push notification the moment its next story breaks.